Treatment with CEA-TCB triggered secretion of pro-inflammatory cytokines (IFNγ, TNFα, IL-2) and several chemotactic molecules (CXCL9, CXCL10, CXCL11, CXCL13) indicating the generation of a highly inflamed tumor microenvironment (Figure 1F). The gene discussed is CXCL13; the disease is neoplasm.